Patent details

300941 Product Name: Canakinumab

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300941
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2848258
Status:
Refused Art. 10 of the EC Regulations
Application number:
300941
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)

Marketing Authorization

Marketing Authorization Number:
C(2017)1412
Marketing Authorization Type:
EEA
Marketing Authorization Date:
23/02/2017
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
08/06/2018
First Marketing Authorization date:
23/02/2017
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
13/06/2018
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
21/12/2020

Applicant/holder

From:
08/06/2018
 
 

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 BASEL, Switzerland (CH)

Agent

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
08/06/2018
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
52/20
Publication date:
23/12/2020
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
26/18
Publication date:
20/06/2018
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
21/12/2020 Outgoing Correspondence Decision refusal 3 PDF /6/8/4/1/8/0800281486/docs/300941_8_385504l527a.pdf
14/10/2020 Outgoing Correspondence Letter to applicant 1 PDF /6/8/4/1/8/0800281486/docs/300941_5_372442l173.pdf
13/10/2020 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /6/8/4/1/8/0800281486/docs/300941_4_incomingcorrespondencepaper20210310032418735.pdf
14/07/2020 Outgoing Correspondence Letter to applicant 3 PDF /6/8/4/1/8/0800281486/docs/300941_6_353991l173.pdf
13/06/2018 Outgoing Correspondence Confirmation receipt request 1 PDF /6/8/4/1/8/0800281486/docs/300941_3_212444l174.pdf
08/06/2018 SPC Documents Annex SPC 10 PDF /6/8/4/1/8/0800281486/docs/300941_0_supplprotectioncertificate20200526050947792.pdf
08/06/2018 SPC Documents Accompanying letter SPC 4 PDF /6/8/4/1/8/0800281486/docs/300941_1_supplprotectioncertificate20200922010814038.pdf
08/06/2018 SPC Documents Marketing Authorization SPC 3 PDF /6/8/4/1/8/0800281486/docs/300941_2_supplprotectioncertificate20180613105233252.pdf
08/06/2018 Application Form First filed application form 2 PDF /6/8/4/1/8/0800281486/docs/300941_7_applicationform20180613105233091.pdf
08/06/2018 SPC Documents Summary of the characteristics of the product 78 PDF /6/8/4/1/8/0800281486/docs/300941_9_supplprotectioncertificate20180613105233386.pdf
08/06/2018 SPC Documents Annex SPC 66 PDF /6/8/4/1/8/0800281486/docs/300941_10_supplprotectioncertificate20180613105233532.pdf
08/06/2018 SPC Documents Annex SPC 4 PDF /6/8/4/1/8/0800281486/docs/300941_11_supplprotectioncertificate20180613105233446.pdf